MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$4.35
0.21 (5.21%)
▲
5d:
+2.0%
30d:
+10.0%
90d:
+18.07%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MDXG trades at premium valuation expecting 8.0% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: MDXG trades at premium valuation expecting 8.0% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $4.34, which is considered extended relative to its 30-day fair value range of $3.99 to $4.32. From a valuation perspective, the stock is trading at a premium (Forward PE: 34.4) compared to its historical average (27.3). At these levels, the market is pricing in 8.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is showing sideways momentum. Immediate support is located at $3.76, while resistance sits at $4.49. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.60 (+59.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MDXG is showing sideways momentum. Immediate support is located at $3.76, while resistance sits at $4.49. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.60 (+59.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.99 -
$4.32
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 59.8% below Wall St target ($6.60)
- NEUTRAL: Trading at premium valuation - market expects 8.0% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$3.99 -
$4.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.76
Resistance Level
$4.49
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.42
Wall Street Target
$6.60
(+59.8%)
Revenue Growth (YoY)
-33.1%
Earnings Growth (YoY)
99.5%
Profit Margin
7.9%
Valuation Premium vs History
+8.0% premium
PE vs Historical
34.4 vs 27.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.0%
(market-implied from PE analysis)
1-Year Target
$4.46
(+8%)
2-Year Target
$4.82
(+17%)
3-Year Target
$5.20
(+26%)
3-Yr Target (if PE normalizes)
(PE: 34→27)
PE COMPRESSION
$4.13
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 21.35 | Current EPS (TTM): $0.20
Bull Case
$2.82
(-32%)
Analyst growth -40.0%, PE expands to 23.5
Base Case
$2.56
(-38%)
Market implied -40.0%, PE stable at 21.4
Bear Case
$2.90
(-30%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 3:13 PM ET
Data refreshes hourly during market hours. Next update: 4:13 PM
Data refreshes hourly during market hours. Next update: 4:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
